Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study
Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study
Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study
Hiroshi Nakase, Remo Panaccione, Severine A.R.A. Vermeire, Dolly Sharma, Valencia P. Remple, Michelle Kujawski, Gary R. Lichtenstein, Silvio Danese, Hannah Palac, Sarah Camille Glover, Peter Higgins, Jason Eccleston, Xuan Yao, Jean-Frédéric Colombel, S Schreiber, Smitha Suravaram, Ziqian Geng
Tulane University (US), Sapporo Medical University (JP), Vita-Salute San Raffaele University (IT), University of Calgary (CA), University of Michigan (US), AbbVie (United States) (US), IRCCS Ospedale San Raffaele (IT), University of Pennsylvania (US), Icahn School of Medicine at Mount Sinai (US), KU Leuven (BE)
Funders
Eli Lilly and Company, Pfizer, National Institutes of Health